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Abstract 
Quinolones are potent antimicrobial agents with a basic chemical structure of bicyclic ring. Fluorine atom at position 
C-6 and various substitutions on the basic quinolone structure yielded fluoroquinolones, namely norfloxacin, cipro-
floxacin, levofloxacin, moxifloxacin and numerous other agents. The target molecules of quinolones and fluoroqui-
nolones are bacterial gyrase and topoisomerase IV enzymes. Broad-spectrum and excellent tissue penetration make 
fluoroquinolones potent agents but their toxic side effects and increasing number of resistant pathogens set limits on 
their use. This review focuses on recent advances concerning quinolones and fluoroquinolones, we will be summa-
rising chemical structure, mode of action, pharmacokinetic properties and toxicity. We will be describing fluoroqui-
nolones introduced in clinical trials, namely avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and non-fluorinated 
nemonoxacin. These agents have been proved to have enhanced antibacterial effect even against ciprofloxacin resist-
ant pathogens, and found to be well tolerated in both oral and parenteral administrations. These features are going to 
make them potential antimicrobial agents in the future.
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Background
Quinolones are potent synthetic antimicrobials first 
developed in the 1960s. Since then several agents have 
been synthetised by modification of basic bicyclic chemi-
cal structure. Quinolones and fluoroquinolones are 
classified based on their chemical structure, antibacte-
rial spectrum and pharmacokinetic features. Each agent 
inhibits bacterial DNA synthesis by forming a ternary 
complex with a DNA molecule and gyrase and topoi-
somerase IV enzymes, thus blocking bacterial DNA 
supercoiling [1–3].
The first quinolone agents were nalidixic acid, cinoxa-
cin and oxolinic acid, each had basic bicyclic quinolone 
ring. These agents achieved 20–40  mg/L peak serum 
concentrations (Cmax) after a treatment with doses of 
500–1000  mg. These agents and their metabolites were 
excreted by kidney and they reached 500–1000  mg/L 
peak urine concentrations 2–4  h following adminstra-
tion. The narrow-spectrum activity of these quinolones 
limited their use in clinical practice [4, 5].
Substituents on certain part of quinolone ring can 
increase potency of agents namely, in position C1 cyclo-
propyl or difluorophenyl, in position C6 a fluorine and in 
position C8 a halogen, metoxy or fused third ring. Qui-
nolones harbouring a piperazin in position C7 are more 
effective on Gram-negatives and target topoizomerase 
IV. Agents targeting both gyrase and topoisomerase IV 
result have broad-spectrum effect [5].
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The addition of fluorine and other substituents on 
the basic quinolone structure yielded fluoroquinolones, 
namely ofloxacin, ciprofloxacin, norfloxacin, pefloxa-
cin, levofloxacin, moxifloxacin and several additional 
agents. These structural changes enhanced their tissue 
penetration as they achieved therapeutic concentrations 
in kidney, lung and intestine. Besides improved pharma-
cokinetic parameters, activity spectrum of these agents 
was also enhanced, as they showed bactericidal effect 
against numerous pathogens including Gram-positives, 
Gram-negatives, aerobes and anaerobes, moreover, anti-
bacterial effect of fluoroquinolones is considered to be 
concentration-dependent [6, 7].
Ciprofloxacin is the most widely used fluoroquinolone 
agent with a potency against Gram-negatives. Levoflox-
acin (stereoisomer of ofloxacin) has bactericidal effect 
against Gram-negative and Gram-positive pathogens. 
Moxifloxacin is characterized by antibacterial effect 
mainly against Gram-positives including anaerobes, 
although they lack potency against Gram-negative anaer-
obes (e.g.: Bacteroides sp.) [8].
Gemifloxacin has also antibacterial activity against 
Gram-positive anaerobes. Garenoxacin, lacks fluorine in 
position 6, thus belonging to desfluoroquinolone group 
[2].
Despite the fact that numerous fluoroquinolone agents 
have been produced in the last decades, only a few of 
them are marketed, and some of them have been with-
drawn or restricted because of their toxicity [7]. The 
most frequent reasons for withdrawal included tendini-
tis after treatment with pefloxacin; rashes appeared after 
sparfloxacin and clinafloxacin therapy; electrocardiogram 
disorders such as QTc prolongation occured during gre-
pafloxacin administration; gatifloxacain and clinafloxacin 
therapy led to dysglycemia; hemolysis occured during 
temafloxacin administration; hepatotoxicity was found 
in trovafloxacin treatment [2, 7, 9]. The pharmacokinetic 
properties of quinolones are listed in Table 1.
In the past years, identification of new molecules were 
in focus to obtain antibacterial agents with potency 
against pathogens that already developed resistance to 
fluoroquinolones. Structure–activity relationship studies 
played key role to detect substituents that had high affin-
ity for binding to both DNA gyrase and topoizomerase 
IV enzymes. Among developed agents five are undergo-
ing clinical testing and all showed enhanced antibacterial 
activity including strains exhibiting resistance to present-
day fluoroquinolones. These agents are avarofloxacin 
(JNJ-Q2), delafloxacin (WQ-3034), finafloxacin (BAY35-
3377), zabofloxacin (DW224a) and non-fluorinated 
nemonoxacin (TG-873870).
Avarofloxacin (JNJ-Q2) (Fig. 1) is an aminoethylidenyl-
piperidine fluoroquinolone with a zwitterion structure 
that demonstrates antibacterial effect against numer-
ous Gram-positive bacteria with a 0.12  mg/L MIC90 
value, therefore it is found to be more potent than pre-
viously used fluoroquinolones. Tested pathogen bacteria 
included strains of Streptococcus pneumoniae, methicil-
lin-resistant Staphylococcus aureus (MRSA), Enterococ-
cus sp., Escherichia coli, Klebsiella spp., Haemophilus 
influenzae and Pseudomonas aeruginosa [10] (Table  2). 
Besides, avarofloxacin showed a potent antibacterial 
Table 1 Pharmacokinetic features of quinolones
Ref reference number
Urinary fraction urinary fraction excreted unbound
















Ciprofloxacin 20–40 40–50 70 4.3 4 [6]
Levofloxacin 24–38 87 99 6.2 6–7 [6]
Sparfloxacin 45 10 92 1.1 20 [6]
Trovafloxacin 76 6 88 2.1 9.6 [6]
Moxifloxacin 50 20 90 4.5 12 [6]
Gatifloxacin 20 72 96 3.8 7.8 [6]
Avarofloxacin 65 12 65 2 14 [12]
Delafloxacin 16 n.a. n.a. 10 12 [39]
Finafloxacin n.a. 33 n.a. 11 10 [19]
Zabofloxacin n.a. n.a. n.a. 2 8 [27]
Nemonoxacin 16 n.a. n.a. 5 15 [40]
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effect against Neisseria gonorrhoeae with a 0.25  mg/L 
MIC90 value, compared to 16 mg/L of ciprofloxacin [11].
Pharmacokinetics
Avarofloxacin is applicable both in per os and in paren-
teral administration. In the case of parenteral dosing 
of 90  min avarofloxacin serum concentration declines 
biexponentially with a short distribution phase and an 
extended terminal phase. During oral dosing the con-
centration decreased monoexponentially. Mean half-life 
time of agent was found similar for 15 and 30 mg doses 
13.4 and 12.9 h, respectively. In the case of 75 and 150 mg 
doses showed 15.1 and 16.7 h. A single 250 mg oral ava-
rofloxacin dose reached its Cmax in 2.18  mg/L 2  h after 
administration. The bioavailability of avarofloxacin is 
65–66 % in parenteral—oral administration [12].
Toxicity
Avarofloxacin was well tolerated during single intrave-
nous (iv) administration up to the maximum dose of 
150  mg. Frequent, mild adverse events were observed 
including headache and contact dermatitis. All adverse 
events were grade I including a transient diarrhea and 
lipase elevation after administration of 75 mg, while phle-
bitis appeared after a 15 mg iv dose.
Multiple iv doses were also well tolerated up to 150 mg 
twice daily adminstration, as nausea, vomiting, diarrhea, 
headache and chills appeared [12].
Delafloxacin (WQ-3034) (Fig.  2) has a chemical 
structure of 1-(6-amino-3,5-difluoro-2-pyridinyl)-
8-chloro-6-fluoro-7-(3-hydroxy-1-azetidinyl)-4-oxo-
1,4-dihydro-3-quinolinecarboxylate, which differs in 
three features from classical fluoroquinolones: in posi-
tion C7 it lacks a strongly basic group this confers weak 
acidity; in position C8 a chlorine exhibits a strong elec-
tron-withdraw on aromatic ring; in position N1 a heter-
oaromatic substitution leads to a larger molecular surface 
compared to current fluoroquinolones [13]. At neutral 
pH, delafloxacin exists in a deprotonated form [14]. Dela-
floxacin targets both DNA gyrase and topoisomerase IV 
Fig. 1 Avarofloxacin




MIC range MIC90 Ref.
S. pneumoniae Avarofloxacin 0.06–0.5 0.25 [10]
ciprofloxacin 8–64 64 [10]
Delafloxacin n.a. n.a. n.a.
Finafloxacin 0.5–4 2 [41]
Zabofloxacin 0.015–0.06 0.03 [24]
Nemonoxacin 0.03–1 0.06 [34]
S. aureus, MRSA FQ-
resistant
Avarofloxacin 0.015–2 0.25 [10]
Ciprofloxacin 4 ≥ 256 64 [10]
Delafloxacin ≤0.004–0.12 0.06 [15]
Finafloxacin 0.25–32 4 [41]
Zabofloxacin 0.016–64 32 [26]
Nemonoxacin 0.5–1 1 [34]
S. aureus, MRSA FQ-
susceptible
Avarofloxacin 0.008–0.015 0.008 [42]
Ciprofloxacin 0.25–1 0.5 [42]
Delafloxacin 0.008–1 0.5 [13]
Finafloxacin 0.06–0.125 0.125 [41]
Zabofloxacin 0.016–1 0.125 [26]
Nemonoxacin ≤0.008–0.12 0.06 [31]
E. faecalis Avarofloxacin 0.03–1 0.5 [10]
Ciprofloxacin 0.5–>16 >16 [10]
Delafloxacin n.a. n.a. n.a.
Finafloxacin 1–2 n.a. [22]
Zabofloxacin 0.008 ≥ 4 2 [24]
Nemonoxacin 0.12–8 4 [34]
E. faecium Avarofloxacin 0.25–4 4 [10]
Ciprofloxacin 1 ≥ 16 >16 [10]
Delafloxacin n.a. n.a. n.a.
Finafloxacin n.a. n.a. n.a.
Zabofloxacin 2–32 16 [24]
Nemonoxacin 0.06–16 16 [34]
E. coli Avarofloxacin 1–16 16 [10]
Ciprofloxacin 16 ≥ 256 256 [10]
Delafloxacin 2–128 n.a. [43]
Finafloxacin 16 ≥ 256 256 [41]
Zabofloxacin 0.015–64 1 [24]
Nemonoxacin 0.5–32 32 [31]
K. pneumoniae Avarofloxacin ≤0.015–1 0.25 [10]
Ciprofloxacin ≤0.004–1 0.25 [10]
Delafloxacin n.a. n.a. n.a.
Finafloxacin 0.015–0.6 n.a. [22]
Zabofloxacin 0.06–8 1 [24]
Nemonoxacin 0.5–32 2 [31]
P. aeruginosa Avarofloxacin 0.5–4 2 [10]
Ciprofloxacin 0.12–1 0.5 [10]
Delafloxacin 0.016–1 n.a. [43]
Finafloxacin 0.25–8 2 [41]
Zabofloxacin <0.008 ≥ 64 >64 [24]
Nemonoxacin 0.12–32 32 [31]
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enzymes making it a potent agent. The anionic struc-
ture of delafloxacin appears to enhance its potency in 
an acidic environment, therefore its antibacterial activ-
ity is increased in environments with reduced pH (e.g.: 
phagolysosome, inflammatory cells) or in skin and soft 
tissue infections of S. aureus. This feature makes dela-
floxacin special among fluoroquinolones as ciprofloxacin 
and moxifloxacin have less activity in acidic sites [14, 15]. 
Besides its direct antibacterial effect, the inhibition of S. 
aures biofilm production was also detected [16].
Pharmacokinetics
Efficacy of delafloxacin was analyzed in a phase 2, mul-
ticenter, randomized, double-blind study. Delafloxacin’s 
antibacterial effect was compared to tigecycline in skin 
and soft tissue infections of 150 patients. Two different iv 
doses of delafloxacin of 300 and 450 mg were administered 
every 12 h and compared to tigecycline given iv in doses of 
100 mg plus iv 50 mg every 12 h. The study was performed 
for 5–14 days based on clinical outcome. No significant dif-
ferences were found between the three treatment options 
as each was effective in both S. aureus and MRSA skin and 
soft tissue infections. The ciprofloxacin MIC values of the 
pathogens ranged between 0.12 and 32  mg/L, while for 
delafloxacin it varied between 0.004 and 0.12 mg/L [15].
A phase 1 single-dose study analyzed efficacy of dela-
floxacin under different feeding conditions. Altogether 30 
healthy individuals were enrolled where each sequence 
comprised 3 treatments of a single per os dose of 900 mg 
delafloxacin under fasting conditions for at least 10  h 
(group A), under fed conditions of standardized FDA 
high fat breakfast 30  min before dosing (group B) and 
in fasting followed by a high fat meal 2  h after dosing 
(group C). The pharmacokinetic parameters of delafloxa-
cin was analyzed in each group; Cmax was 11.5, 9.14 and 
11.8 mg/L in the corresponding group. The time to reach 
Cmax was found 1.25, 2.5 and 1.5 h while half-life time of 
delafloxacin was 14.1, 12.9 and 12 h, respectively [17].
Toxicity
Delafloxacin was well-tolerated during the multicenter 
study, although adverse events of nausea, diarrhea, head-
ache, insomnia and fatigue appeared in iv administered 
300 mg and 450 mg delafloxacin groups [15].
In phase 1 single dose trial, delafloxacin was also well 
tolerated but following adverse events appeared in A, B 
and C groups: diarrhea, nausea, presyncope, headache, 
vaginal infections or pharyngitis [17].
Finafloxacin (BAY35-3377) (Fig.  3) is a fluorinated 
quinolone derivative with 8-cyano-substituent and 
7-pyrrolo-oxazinyl moiety. It has a zwitterion chemical 
structure with an isoelectric pH of 6.7 and two dissocia-
tion constants at a pKa1 of 5.6 (carboxylate function) and 
a pKa2 of 7.8 (nitrogen at C7 substituent), in contrast to 
ciprofloxacin with an isoelectric pH of 7.4 and two dis-
sociation constants at pKa1 of 6.1 and pKa2 of 8.7 [18]. 
Finafloxacin has enhanced antibacterial activity under 
acidic conditions, this is unique among fluoroquinolo-
nes and advantageous in specific infection sites namely, 
skin and soft tissue, vagina and urinary tract. The maxi-
mum bactericidal activity was observed at pH 5–6. 
However, at neutral pH the antibacterial activity was 
similar to the previously used fluoroquinolones [19]. 
These properties of finafloxacin could offer advantage 
in treatment of infections in acidic anatomical sites or 
in inflammatory processes in acidic environment, such 
as respiratory and urinary tracts, skin and intraabdomi-
nal sites. Antibacterial activity in acidic pH conditions 
might be benefitial in Helicobacter pylori eradication 
too [20]. Furthermore, antibacterial effect of finafloxa-
cin against phagocytized Legionella pneumophila and 
Listeria monocytogenes was investigated. Finafloxacin 
was found to be more potent against L. pneumophila 





MIC range MIC90 Ref.
H. influenzae Avarofloxacin 0.008–0.015 0.015 [10]
Ciprofloxacin 0.008–0.015 0.015 [10]
Delafloxacin n.a. n.a. n.a.
Finafloxacin n.a. n.a. n.a.
Zabofloxacin <0.008–0.008 0.008 [24]
Nemonoxacin ≤0.008–0.06 n.a. [38]
Fig. 2 Delafloxacin
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than ciprofloxacin, although against L. monocytogenes it 
was less effective [21].
Pharmacokinetics
Plasma pharmacokinetics of finafloxacin was ana-
lyzed after orally administered single doses of 25, 50, 
100, 200, 400 and 800  mg. The Cmax values were: 0.24, 
0.44  ±  0.16, 1.32  ±  0.62, 1.90  ±  0.73, 5.06  ±  2.09 and 
11.1  ±  2.96  mg/L, respectively. The half life-time of 
finafloxacin in single dose administration were as fol-
lows: 1.28, 3.8 ± 2.7, 7.2 ± 3.2, 4.6 ± 1.9, 10.0 ± 4.4 and 
10.5 ± 2.2 h, respectively. The time to reach the Cmax var-
ied between 0.5 and 1 h.
In the case of multiple doses of 150, 300, 600 and 
800  mg were administered orally once daily for seven 
consecutive days. The Cmax after the seventh day showed 
the following concentrations: 1.50  ±  0.52, 4.15  ±  2.11, 
6.76 ± 2.2 and 8.95 ± 3.11 mg/L. The corresponding half-
life time was 5.3 ± 0.6, 6.5 ± 2.5, 8.8 ± 3.1 and 14 ± 5.5 h, 
respectively. While time to reach Cmax was between 0.5 
and 1.5 h [19].
Accumulation of finafloxacin was not relevant follow-
ing daily once application of doses up to 800  mg over 
7 days. Peak serum concentrations may slightly increase 
proportionally compared to dose [19].
The urine recovery data show that around 30 % of oral 
dose can be detected. Moreover, the urine finafloxacin 
concentration exceeds MIC values determined in Muel-
ler–Hinton broth for many pathogens of urinary tract 
infections e.g.,: E. coli and P. aeruginosa. This feature 
makes it advantageous in treatment of several urinary 
tract infections [21, 22].
The mean concentration of finafloxacin in urine 
was 68  mg/L in the first 4  h and 4  mg/L at the time of 
12–24 h sampling following 200 mg dose. In the case of 
the 800 mg dose the mean finafloxacin concentration was 
112 mg/L in the first 4 h (peak of 150 mg/L was reached 
in the 4–8 h interval) and 18 mg/L in the 12–24 h sam-
pling period [23].
Toxicity
Finafloxacin is found to be well-tolerated agent, although 
minor adverse events were detected such as central nerv-
ous system events including headaches. Gastrointestinal 
and respiratory disorders appeared, namely diarrhea, 
loose stool, nausea, flatulence, rhinitis and nasopharyn-
gitis. Frequency of adverse events did not vary between 
the different administered doses and their corresponding 
placebo groups, except for gastrointestinal events, as they 
appeared during actively treated subjects [19].
Zabofloxacin (DW-224a) (Fig.  4) is a broad-spectrum 
fluoroquinolone as it achieves bactericidal effect against 
various Gram-positive and Gram-negative pathogens, 
even against fluoroquinolone resistant ones [24–26]. Two 
formulations of zabofloxacin are available, namely zabo-
floxacin hydrochloride (DW-224a) and aspartate (DW-
224aa) [27].
Pharmacokinetics
Zabofloxacin hydrochloride and aspartate were analyzed 
in a random, open-label single-dose study with enroll-
ment of twenty-nine healthy males. The pharmacokinetic 
parameters were set after oral adminstration of 366.7 mg 
zabofloxacin hydrochloride and 366.5  mg zabofloxacin 
aspartate. Cmax values were 1.9 ± 0.5 and 2 ± 0.3 mg/L 
and these concentrations were reached in plasma 
between 0.5 and 4 h and 0.8–3 h, respectively. The half-
life time of zabofloxacin was 8 ±  1  h for both formula-
tions [27].
Pharmacokinetic parameters of zabofloxacin hydro-
chloride were analyzed in beagle dogs. Orally adminis-
tered zabofloxacin hydrochloride was given in 10, 30 and 
90  mg/kg/day for a total of 4  weeks. The absorption of 
the agent was fast, as 30 min after administration plasma 
zabofloxacin concentration was detected. Cmax was 
10 mg/L and time to reach it was 1 h [28].
Fig. 3 Finafloxacin
Fig. 4 Zabofloxacin
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Zabofloxacin pharmacokinetic parameters were also 
investigated in a rat model. 20  mg/kg single dose zabo-
floxacin hydrochloride was orally administered to the 
animals. Cmax was 1.8  ±  0.8  mg/L and it was reached 
within 33.8 ± 18.9 min. The half-life time of zabofloxacin 
was 107 ± 13.3 min [29, 30].
Toxicity
Single oral dose of both formulations of zabofloxacin 
were found to be well-tolerated among healthy male vol-
unteers. The most frequent adverse events were nausea 
(7  % of the subjects), hypotension (3  %), somnolence 
(3 %), increase of blood phosphokinase (3 %). By contrast, 
prolongation of QT interval a typical adverse event of 
fluoroquinolones was not detected [27].
Subacute toxicity was analyzed in beagle dogs. All 
tested animals presented vomiting and salivation at 
30 and 90  mg/kg/day doses, although only one subject 
showed these adverse events at 10 mg/kg/day dose. Ano-
rexia, decreased food intake and body weight gain was 
detected in 90 mg/kg/day group during the 20th and the 
28th days. Significant serum total cholesterol increase 
was detected in the 30 and 90  mg/kg/day group in the 
fourth week of the study. Electrocardiogram showed 
a trend toward increased QT intervals at 90  mg/kg/
day groups. Atrophy of testicles was observed and con-
sequently, oligo and aspermia were detected. Thymus, 
spleen and adrenal gland atrophy was found in 30 and 
90 mg/kg/day doses [28].
Nemonoxacin (TG-873870) (Fig. 5) is a C-8-metoxy non-
fluorinated broad-spectrum quinolone, generally more 
active than classic fluoroquinolones. The C-8-methoxy 
substituent on the quinolone ring increases antibacte-
rial effectiveness against Gram-positives and reduces 
selection of resistant mutants. The lack of fluorine may 
decrease frequency of toxic adverse effects [31–33]. 
In  vitro testing found that antibacterial activity of 
nemonoxacin is better against methicillin susceptible and 
resistant S. aureus [34].
Pharmacokinetics
Pharmacokinetic parameters of nemonoxacin were inves-
tigated in a multiple-parameter study in healthy sub-
jects. 500 or 750  mg of nemonoxacin was administered 
parenterally during 1.5 and 2.25  h and rate of 5.56  mg/
min, once daily for 10 days continuously. In a randomized 
double-blind placebo controlled study 500, 650 or 750 mg 
of nemonoxacin or placebo was administered to healthy 
individuals parenterally during of 2 or 2.6 or 3 h at a rate 
of 4.17 mg/min, once daily for 10 days continuously [35]. 
Blood and urine nemonoxacin concentrations were ana-
lyzed by validated liquid chromatography–tandem mass-
spectrometry (LC–MS/MS).
In the first stage, the maximal nemonoxacin concen-
trations were 9.6 ±  1.84 and 11 ±  2.2  mg/L during the 
administration of 500 and 750  mg whereas areas under 
concentration–time curve between 0 to 24  h (AUC0-24) 
were 44.03 ± 8.62 and 65.82 ± 10.78 µg h/ml.
Nemonoxacin drug accumulation was not relevant 
during a 10 days’ administration of both 500 and 750 mg 
[35].
Two-compartment model was used to analyze nemon-
oxacin pharmacokinetic profiles in healthy volunteers. 
Nemonoxacin distribution volumes in central compart-
ment were in range of 64.5–83.2 L, whereas in peripheral 
one they ranged between 24.7 and 40.9 L.
The distribution half-life time of nemonoxacin showed 
dose-dependency. In case of parenteral administration of 
500 mg (at 5.56 mg/min rate) 2.42 h while in the 750 mg 
dose it increased to 3.37 h. Increase in the corresponding 
elimination half-life time was from 10.8 to 12.7 h. By con-
trast, a slight decrease in the intercompartment clearance 
was seen when nemonoxacin concentration increased as 
nemonoxacin clearance rates ranged between 12.0 and 
14.6 L/h [35].
Adminstration of nemonoxacin was analyzed for both 
oral and parenteral 500 and 750 mg dosing. Interestingly, 
the iv nemonoxacin Cmax (at infusion rate of 4.17  mg/
min) was similar to the orally administered 500  mg 
nemonoxacin: 7.13 and 7.02  mg/L. In case of 750  mg 
administration Cmax values for iv and oral dosing were: 
9.96 and 9.13 mg/L [36].
Toxicity
Safety and toxicity of nemonoxacin were tested in healthy 
volunteers. The highest tolerable dose during iv nemon-
oxacin administration was 1250  mg and the most suit-
able infusion rate was 5.56 mg/min. Transient and mild 
adverse events appeared, namely injection site reac-
tion, erythematous rashes with or without pruritus and 
Fig. 5 Nemonoxacin
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abnormal electrocardiogram T-wave. All the above men-
tioned adverse events vanished during application or 
within 2  h after application, except in two individuals, 
one who received a dose of 750 mg at 4.17 mg/min infu-
sion rate and another person also from the 750 mg dose-
group, at 8.33 mg/min infusion rate [37].
In a study conducted with orally administered 500 and 
750  mg nemonoxacin, the 44.9 and 55.8  % of subjects 
produced treatment emergent adverse events. A control 
group was also included in this study, where 500  mg of 
levofloxacin was administered and 48.9  % of subjects 
showed adverse events. Diarrhea, dizziness, headaches 
appeared in each group [38].
Conclusions
Several attempts were followed to recognize antibacterial 
agents with new chemical structures, although numerous 
novel agents are derived from current antibiotic classes. 
The newly discovered agents should demonstrate more 
potent antimicrobial activity, efficacy against resist-
ant pathogens, yield improved safety profiles and show 
enhanced pharmacokinetics. Based on pharmacological 
experience it is possible to design new molecules with 
improved pharmacokinetic and pharmacodynamic fea-
tures in old antibiotic classes. The sophisticated crystal-
lographic methods and structure–activity relationship 
studies play crucial role in drug discovery to detect mul-
tiple targets of a known antibiotic class.
The novel quinolone agents detailed in this review 
offer an improved antibacterial effect compared to earlier 
classes of fluoroquinolones. These antibiotics proved to 
have enhanced bactericidal activity even against various 
ciprofloxacin pathogens this confirms their role in treat-
ment of numerous infections. The improved tolerability, 
safety profile and decreased toxicity enable them to be 
used in clinical practice.
The doses of all antibiotics should be well established on 
pharmacokinetic and pharmacodynamic properties, thus 
reducing selection of resistant mutants. Still, more infor-
mation are required regarding efficacy against multidrug-
resistant pathogens. These resistant strains are main targets 
for new drugs. Resistance determinants are well under-
stood, so new molecules can be designed on a molecular 
level to avoid the most common resistance mechanisms. 
Furthermore, it is necessary to explore targets to serve as 
basis for new antibacterial agents in the future.
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